Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes.
about
Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic.Predicting neutropenia risk in patients with cancer using electronic data.Feasibility and safety of a reduced duration of therapy of colony-stimulating factor in a dose-dense regimen.Incidence of Neutropenia in Veterans Receiving Lung Cancer Chemotherapy: A Comparison of Administrative Coding and Electronic Laboratory Data.Are specialty drug prices destroying insurers and hurting consumers?: a number of efforts are under way to reduce price pressure.G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use.Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia.Cancer care burden: aiming at the Achilles heelUptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer.Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.Cancer Care Delivery Research: Building the Evidence Base to Support Practice Change in Community OncologyA way forward on the medically appropriate use of white cell growth factorsMedical oncologists' perceptions of financial incentives in cancer care.Neutropenia and G-CSF in lymphoproliferative diseases.Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice.Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practiceColony-stimulating factors for febrile neutropenia during cancer therapy.Use of colony-stimulating factor in patients with ovarian cancer receiving paclitaxel and carboplatin in Japan.Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines.Pegfilgrastim: a review of the pharmacoeconomics for chemotherapy-induced neutropenia.The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia.New G-CSF agonists for neutropenia therapy.Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review.Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia.Pegfilgrastim use and bone pain: a cohort study of community-based cancer patients.Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.Impact of recommended weight-based dosing of granulocyte-colony stimulating factors in acute leukemia and stem cell transplant patients.Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor.Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy--a representative sample survey in Germany.Increasing utilization and predictors of hematopoietic growth factors in patients diagnosed with colorectal cancer: findings from a large national population-based cohort in the USA, 1992-2009.Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis.Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.Re: personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.Efficacy, safety and proper dose analysis of PEGylated granulocyte colony-stimulating factor as support for dose-dense adjuvant chemotherapy in node positive Chinese breast cancer patients.A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study.Time trends in utilization of G-CSF prophylaxis and risk of febrile neutropenia in a Medicare population receiving adjuvant chemotherapy for early-stage breast cancer.Weak circadian rhythm increases neutropenia risk among breast cancer patients undergoing adjuvant chemotherapy.Management and cost analysis of cancer patients treated with G-CSF: a cohort study based on the French national healthcare insurance database.
P2860
Q27001627-AA28550D-07FE-4139-A416-BD5088E5C48EQ31131362-16481ECE-53E0-4A45-8428-D1A25298266BQ33414659-4BC07974-2061-4A04-9C5D-7CF21BEED092Q33557215-DA3A3DEF-C682-4C6E-A612-9849DCC9C4B3Q34010544-5A19CD6B-3C8D-48B4-8FF7-1D365B6DAE2BQ34982532-FFCF28A3-85BA-4949-AC71-C39A33B6F418Q35044368-2926361F-EFC9-4391-B4B9-C375FF1E7D61Q35714571-6F29C91F-F88F-4A1C-A089-6CAE12E2DE0EQ35808451-F074958A-EB27-4A9D-8B7F-746883FA9CA7Q36000209-B27B9DDB-C538-4B14-B6BD-A1035160B755Q36026000-1D69D8A9-E411-4CCA-8F8A-1247FC915F2EQ36058245-EC662185-C000-439F-98D7-FA7BE40F2F8BQ36589617-A477F409-4F4E-45F0-A943-0BF2CB9913CAQ36828921-0C889077-0460-4F64-941F-E48132C86956Q36840636-74085779-CB42-4021-989B-F1320B2F647FQ37554901-A7E2AF8F-FDAA-4DE4-82E4-78282114A88DQ37626772-13A6E8C1-5173-41D7-91B2-E5C60B4EFE04Q37717738-F917B436-A3FB-471E-BAD5-203EFDF669AFQ37996443-90C5CCF0-AA0A-4B8E-BFDF-FA6E7FEE147FQ38068457-8FF42BFB-5F76-475F-84E3-E278D24084BAQ38092732-ED9099AC-5D27-4353-A4A0-8CF4D2ABEBD6Q38145338-9B7D49D5-830E-4C9E-8FE7-827A3F8B8FD6Q38225700-1EAC3CE0-11E8-4A16-8C89-C2B27033E706Q38256944-0C1019F3-91B7-4B2C-A673-772E0304561CQ38468072-25BE6655-45C1-466B-A482-B52E41388383Q38613025-436FDD9E-5943-4371-88A9-B693EC987A71Q39000902-5852E0FD-F4A6-4253-AA7A-A8769FE7A751Q39297322-916591B6-E252-4695-8E10-706E73294331Q40240657-95C7A84E-2F78-4A34-B5CB-DEB95FC84259Q40829486-99202D4B-1106-45C0-9661-A40762313FA8Q41735144-301FAD19-57BC-4A3B-B919-23D01D24D607Q42363042-6B18D2AA-6BC5-48EA-9E0E-3B7346D1FB37Q42540897-5F76B277-3BED-471D-A15E-D17BF1AFE92DQ42766829-DE01A17B-2886-4139-B5E1-D4E1D04C8B12Q43026530-AF895185-18F4-4AC4-92D9-B5832D074AFBQ44834419-F89D5AE1-910B-45C1-AB68-B3ED3AD6B133Q47327831-C5020293-6458-4735-A172-406D0C0BB907Q47969501-BE96D8EE-B10D-438E-8B93-4A0A91DF5C40Q48136904-E97125F2-0E97-4896-B093-5546E84B9265Q48606842-E7DE39F0-90EC-4B53-9F6B-023FCD199ECC
P2860
Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Use of colony-stimulating fact ...... savings and improved outcomes.
@ast
Use of colony-stimulating fact ...... savings and improved outcomes.
@en
type
label
Use of colony-stimulating fact ...... savings and improved outcomes.
@ast
Use of colony-stimulating fact ...... savings and improved outcomes.
@en
prefLabel
Use of colony-stimulating fact ...... savings and improved outcomes.
@ast
Use of colony-stimulating fact ...... savings and improved outcomes.
@en
P2093
P2860
P356
P1476
Use of colony-stimulating fact ...... savings and improved outcomes.
@en
P2093
Arnold L Potosky
Benjamin Kim
Jane C Weeks
Jennifer L Malin
Nadia Howlader
Solomon B Makgoeng
P2860
P304
P356
10.1093/JNCI/DJR152
P407
P577
2011-06-13T00:00:00Z